CYBERDYNE : Financial result briefing for the consolidated nine months ended December 31, 2022

Consolidated Financial Result Briefing

for the Nine Months ended December 31, 2022

CYBERDYNE, Inc. February 14, 2023

Consolidated financial results (IFRS)

Year-on-year comparison for the nine months ended December 31, 2022

Revenue: 2,374M (+76% YoY)

Operating profit: ¥-749M(-93M YoY)

Final profit: ¥68M (Improved by 659M YoY)

(Unit: Millions of yen)

Revenue

(Gross profit)

Operating profit

Profit before tax

Profit attributable to owner of the parent

FY2021

Q1-Q3

1,347

(984)

-656

-554

-590

FY2022

Q1-Q3

2,374

(1,482)

-749

*３ *４

112

68

+/-

+1,027 *1

(+497)

*２

-93

+666

+659

+/-%

+76.3％*1

(+50.5%)

ー

ー

ー

*1 Increase in revenue（1,027M）（YoY）

Rental	+190M (HAL for overseas)
Sales	+54M (Increase of sales of product for research)

Service +782M (Treatment service by RISE Group in USA)

*２ Increase in SG&A (631M) (YoY)

SG&A expenses of consolidated subsidiary acquired through M&A +694M

*３ Exchange gain 55M (in finance income)

*４ Gains related to investment securities 851M （Net）

Finance income (gain on valuation) +588M

Gains related to CEJ +263M

Ref) revenue related to investment securities in the first half of the previous fiscal year 86M (net)

3

Consolidated financial results (IFRS)

Performance trends

【Q3 Results】Revenue +5% QoQ, +59% YoY

(Unit : Millions of yen)

Consolidated statement	FY2021	Q1	FY2022	Q3	Q1-Q3	Quarter on Quarter	Year on Year
of profit or loss	Q3	Q2	+/-	+/-%	+/-	+/-%
Revenue	521	751	791	831	2,374	+41	+5.1%	+310	+59.4%
Cost of sales	156	261	292	339	892	+47	+16.1%	+183	+117.1%
Gross profit	365	490	499	492	1,482	-6	-1.3%	+127	+34.8%
R&D expenses	173	151	182	161	494	-21	-11.3%	-12	-6.7%
Other SG&A	401	568	594	652	1,814	+58	+9.8%	+250	+62.4%
Other income/	34	51	12	13	77	+1	+6.0%	-21	-61.3%
expenses
Operating profit	-175	-178	-264	-307	-749	-43	-	-133	-
Finance income/	3	541	134	10	685	-123	-92.3%	+8	+289.6%
expense
Other	8	9	132	36	176	-96	-72.9%	+28	+371.3%
Profit before tax	-164	372	1	-261	112	-263	-	-97	-
Profit attributable to	-162	241	27	-200	68	-226	-	-37	-
owner of the parent

gain on valuation difference of investments securities +109M, translation of foreign operations -99M

5

Consolidated financial results (IFRS) by types of transaction

Increase service sales by acquiring treatment service locations in the U.S.

2,374

	986
1,347	140
204
85
1,057	1,248

FY2021 Q1-Q3 FY2022 Q1-Q3

(Millions of yen)

Services

+782M

（+383%）

Sales

+54M

（+63%）

Rental +190M

（+18%）

Income from treatment services of RISE Group in the U.S., etc. +750M

Sales revenue from sales of products for research such as Acoustic X*

*Acoustic X：Photoacoustic Imaging device using LED Light array

Increase of HAL rented outside Japan +181M

Service: Revenue from service at a point of time

Sales: Revenue from sales at a point of time

Rental and maintenance: revenue over time

7

Number of operating units

Growth of Medical Lower Limb Type (overseas) and Single Joint Type (domestic) rentals

(Unit: Millions of yen)

	Product classification
	HAL Lower Limb Type
	(Medical)
For Hospitals
HAL Lower Limb Type
(improving function)
(Non-medical)
	HAL Single Joint Type
Care support	HAL Lumbar Type
and well-being
Labor Support	HAL Lumbar Type

FY2021	FY2022	(Ratio)
Q3	Q3
413	505 *１	40%
141	131	10%
92	135 *２	11%
194	178	14%
78	51	4%

*１ HAL Lower Limb Type (Medical)

The main factors of the increase in sales were from APAC and Europe

*２ HAL Single Joint Type

The main factors of the increase in sales were Japanese hospitals

Cleaning/disinfection/transportation robot

39

37 3%

Other

100

210 17%

Total

1,057

1,248 100%

9